

# Effects of Anacetrapib in Patients with Atherosclerotic

New England Journal of Medicine

377, 1217-1227

DOI: [10.1056/nejmoa1706444](https://doi.org/10.1056/nejmoa1706444)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Precision medicine to change the landscape of cardiovascular drug development. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 337-343.	0.4	0
3	Revealing the effect of CETP inhibition in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2017, 14, 635-636.	6.1	39
4	CETP Inhibitors – A New Inning?. <i>New England Journal of Medicine</i> , 2017, 377, 1284-1285.	13.9	23
5	Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8466-8481.	2.9	6
6	Reduction of In-Stent Restenosis by Cholesteryl Ester Transfer Protein Inhibition. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 2333-2341.	1.1	17
7	Acute Coronary Syndromes. <i>Circulation</i> , 2017, 136, 1155-1166.	1.6	329
8	Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. <i>Postgraduate Medicine</i> , 2017, 129, 801-810.	0.9	2
9	Results of the REVEAL study. Why should we not welcome a new lipid-lowering agent?. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2017, 29, 278-279.	0.1	0
10	Familial hypercholesterolaemia. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17093.	18.1	315
11	Cholesterol Ester Transfer Protein Inhibitor Review. <i>Hospital Pharmacy</i> , 2017, 52, 596-598.	0.4	0
12	Role of Payers in the Development of Cardiovascular Therapeutics. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2822-2830.	1.2	5
13	HDL functionality in type 1 diabetes. <i>Atherosclerosis</i> , 2017, 267, 99-109.	0.4	50
14	HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics. <i>Current Cardiology Reports</i> , 2017, 19, 132.	1.3	85
15	The Imminent Demise of Cardiovascular Drug Development. <i>JAMA Cardiology</i> , 2017, 2, 1293.	3.0	10
16	Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin. <i>JAMA Cardiology</i> , 2017, 2, 1385.	3.0	89
17	Resultados del estudio REVEAL. ¿Por qu© no debemos dar la bienvenida a un nuevo agente hipolipemiente?. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2017, 29, 278-279.	0.4	0
18	Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?. <i>Diseases (Basel)</i> , Tj ETQq0,0,0 rgBT /Overlock 1	1.0	14
19	Anacetrapib as a potential cardioprotective strategy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3497-3502.	2.0	9

#	ARTICLE	IF	CITATIONS
20	Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. <i>Cardiovascular Diabetology</i> , 2017, 16, 124.	2.7	107
22	European Society of Cardiology (ESC) Annual Congress Report From Barcelona 2017. <i>Circulation Journal</i> , 2017, 81, 1758-1763.	0.7	3
25	Fasting or Non-fasting Lipids for Atherosclerotic Cardiovascular Disease Risk Assessment and Treatment?. <i>Current Atherosclerosis Reports</i> , 2018, 20, 14.	2.0	11
26	Treating Dyslipidemia in Type 2 Diabetes. <i>Cardiology Clinics</i> , 2018, 36, 233-239.	0.9	11
27	High-Density Lipoprotein Infusions. <i>Cardiology Clinics</i> , 2018, 36, 311-315.	0.9	3
28	Is It Time for New Thinking About High-Density Lipoprotein?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 484-486.	1.1	21
29	Cholesteryl ester transfer protein and its inhibitors. <i>Journal of Lipid Research</i> , 2018, 59, 772-783.	2.0	55
30	PCSK9 inhibitor valuation: A science-based review of the two recent models. <i>Clinical Cardiology</i> , 2018, 41, 544-550.	0.7	7
31	HDL in CKDâ€”The Devil Is in the Detail. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1356-1371.	3.0	65
32	The highs and lows of cardiovascular disease prevention. <i>Atherosclerosis</i> , 2018, 272, 222-224.	0.4	0
33	Low Levels of High-Density Lipoprotein Cholesterol Are Linked to Impaired Clopidogrel-Mediated Platelet Inhibition. <i>Angiology</i> , 2018, 69, 786-794.	0.8	6
34	Cardiovascular outcomes trial with anacetrapib in subjects with high cardiovascular risk â€” are major benefits REVEALed?. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 611-615.	0.9	2
35	Bempedoic Acid (ETC-1002). <i>Cardiology Clinics</i> , 2018, 36, 257-264.	0.9	39
36	Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk. <i>Diabetes and Metabolism</i> , 2018, 44, 508-513.	1.4	40
37	ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein). <i>Circulation</i> , 2018, 138, 1677-1692.	1.6	28
38	Interaction of lecithin:cholesterol acyltransferase with lipid surfaces and apolipoprotein A-I-derived peptides. <i>Journal of Lipid Research</i> , 2018, 59, 670-683.	2.0	16
39	Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. <i>Diabetes Care</i> , 2018, 41, 1275-1284.	4.3	43
40	What have we learnt from the clinical outcomes trials with the cetrapiBs?. <i>Current Opinion in Lipidology</i> , 2018, 29, 327-332.	1.2	5

#	ARTICLE	IF	CITATIONS
41	Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency. <i>Journal of Clinical Lipidology</i> , 2018, 12, 604-614.	0.6	14
42	Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599â€”912 current drinkers in 83 prospective studies. <i>Lancet, The</i> , 2018, 391, 1513-1523.	6.3	858
43	Novel association between CDKAL1 and cholesterol efflux capacity: Replication after GWAS-based discovery. <i>Atherosclerosis</i> , 2018, 273, 21-27.	0.4	5
44	Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?. <i>Cardiology Clinics</i> , 2018, 36, 287-298.	0.9	13
45	Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk. <i>Cardiology Clinics</i> , 2018, 36, 299-310.	0.9	11
46	Insights from population-based analyses of plasma lipids across the allele frequency spectrum. <i>Current Opinion in Genetics and Development</i> , 2018, 50, 1-6.	1.5	9
47	Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies. <i>Atherosclerosis</i> , 2018, 269, 219-228.	0.4	67
48	Challenges in Interpreting Multivariable Mendelian Randomization: Might "Good Cholesterol" Be Good After All?. <i>American Journal of Kidney Diseases</i> , 2018, 71, 149-153.	2.1	15
49	Frontiers in cardiovascular prevention. <i>European Heart Journal</i> , 2018, 39, 329-332.	1.0	2
50	Cardiovascular Risk Beyond Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2018, 71, 633-635.	1.2	7
51	Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: The EPOCHâ€”JAPAN study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 674-684.e5.	0.6	101
52	Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP. <i>Journal of Clinical Lipidology</i> , 2018, 12, 784-800.e4.	0.6	13
53	Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DMâ€”DYSLIPIDEMIA randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1479-1489.	2.2	76
54	Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other) Tj ETQq1 1 0.784314 rgBT /Over 1.6 51	1.6	51
55	From High-Density Lipoprotein Cholesterol to Measurements of Function. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 487-499.	1.1	94
56	New Therapeutic Approaches for Familial Hypercholesterolemia. <i>Annual Review of Medicine</i> , 2018, 69, 113-131.	5.0	19
57	The role of lipoprotein (a) in chronic kidney disease. <i>Journal of Lipid Research</i> , 2018, 59, 577-585.	2.0	77
58	Atherogenic lipoproteins as treatment targets. <i>Nature Reviews Cardiology</i> , 2018, 15, 75-76.	6.1	3

#	ARTICLE	IF	CITATIONS
59	Advances in lipid-lowering therapy through gene-silencing technologies. <i>Nature Reviews Cardiology</i> , 2018, 15, 261-272.	6.1	101
60	Hypolipidemic Drugs and Diabetes Mellitusâ€™ Mechanisms and Data From Genetic Trials. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 187-191.	1.0	5
61	The therapeutic potential of CETP inhibitors: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2018, 28, 331-340.	2.4	17
62	Lipid-lowering treatment in peripheral artery disease. <i>Current Opinion in Pharmacology</i> , 2018, 39, 19-26.	1.7	19
63	Genetics of familial hypercholesterolemia. <i>Current Opinion in Lipidology</i> , 2018, 29, 80-86.	1.2	5
64	High-Density Lipoprotein Function in Cardiovascular Disease and Diabetes Mellitus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, e10-e16.	1.1	39
65	Evolving Role of Nonâ€™Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. <i>Pharmacotherapy</i> , 2018, 38, 164-171.	1.2	7
66	Effects of evolving lipid-lowering drugs on carbohydrate metabolism. <i>Diabetes Research and Clinical Practice</i> , 2018, 137, 1-9.	1.1	2
67	Weight Loss and Exercise Alter the High-Density Lipoprotein Lipidome and Improve High-Density Lipoprotein Functionality in Metabolic Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 438-447.	1.1	49
68	LDL Receptor Gene-ablated Hamsters: A Rodent Model of Familial Hypercholesterolemia With Dominant Inheritance and Diet-induced Coronary Atherosclerosis. <i>EBioMedicine</i> , 2018, 27, 214-224.	2.7	51
69	Present therapeutic role of cholesteryl ester transfer protein inhibitors. <i>Pharmacological Research</i> , 2018, 128, 29-41.	3.1	45
70	The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes. <i>Canadian Journal of Cardiology</i> , 2018, 34, 595-604.	0.8	56
71	Determinants of cholesterol efflux capacity in humans. <i>Progress in Lipid Research</i> , 2018, 69, 21-32.	5.3	77
72	High-Density Lipoprotein Cholesterol and Mortality. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 669-672.	1.1	85
73	From the editor: A run of success in treating atherosclerotic vascular disease. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1-2.	0.6	3
74	LDL cholesterol: How low to go?. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 348-354.	2.3	12
75	The year in cardiology 2017: coronary interventions. <i>European Heart Journal</i> , 2018, 39, 914-924.	1.0	1
76	Plasma apolipoprotein-B is an important risk factor for cardiovascular disease, and its assessment should be routine clinical practice. <i>Current Opinion in Lipidology</i> , 2018, 29, 51-52.	1.2	14

#	ARTICLE	IF	CITATIONS
77	The year in cardiology 2017: prevention. <i>European Heart Journal</i> , 2018, 39, 345-353.	1.0	3
78	Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018, 39, 2526-2539.	1.0	262
79	Pharmacogenomics of blood lipid regulation. <i>Pharmacogenomics</i> , 2018, 19, 651-665.	0.6	3
80	A new perspective on lipid research in age-related macular degeneration. <i>Progress in Retinal and Eye Research</i> , 2018, 67, 56-86.	7.3	162
81	Variations in time to benefit among clinical trials of cholesterol-lowering drugs. <i>Journal of Clinical Lipidology</i> , 2018, 12, 857-862.	0.6	21
82	Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate. <i>Atherosclerosis</i> , 2018, 274, 16-22.	0.4	30
83	Unexplained reciprocal regulation of diabetes and lipoproteins. <i>Current Opinion in Lipidology</i> , 2018, 29, 186-193.	1.2	17
84	Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trial. <i>Journal of Clinical Lipidology</i> , 2018, 12, 741-747.e11.	0.6	6
85	Causal Effect of Lipids and Lipoproteins on Atherosclerosis. <i>Cardiology Clinics</i> , 2018, 36, 203-211.	0.9	26
86	Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations. <i>AAPS Journal</i> , 2018, 20, 46.	2.2	46
87	ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease. <i>JAMA Cardiology</i> , 2018, 3, 401.	3.0	42
88	The Pros and Cons of Mendelian Randomization Studies to Evaluate Emerging Cardiovascular Risk Factors. <i>Current Cardiovascular Risk Reports</i> , 2018, 12, 1.	0.8	1
89	Leveraging model-informed approaches for drug discovery and development in the cardiovascular space. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 355-364.	0.8	4
90	An update on trials of novel lipid-lowering drugs. <i>Current Opinion in Cardiology</i> , 2018, 33, 416-422.	0.8	5
91	Assessing Cardiovascular Disease Risk and Responses to Preventive Therapies in Clinical Practice. <i>Current Atherosclerosis Reports</i> , 2018, 20, 23.	2.0	5
92	Poststatin era in atherosclerosis management. <i>Current Opinion in Lipidology</i> , 2018, 29, 246-258.	1.2	7
93	High-Density Lipoprotein Subspecies Defined by Apolipoprotein CIII and Subclinical Atherosclerosis Measures: MESA (The Multi-Ethnic Study of Atherosclerosis). <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	19
94	Pharmacogenetics and the Promise of Personalized Medicine. <i>JAMA Cardiology</i> , 2018, 3, 408.	3.0	2

#	ARTICLE	IF	CITATIONS
95	Fasting Versus Nonfasting and Low-Density Lipoprotein Cholesterol Accuracy. <i>Circulation</i> , 2018, 137, 10-19.	1.6	92
96	Trials and Tribulations of CETP Inhibitors. <i>Circulation Research</i> , 2018, 122, 106-112.	2.0	210
97	The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 409-418.	2.3	42
98	Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 9-15.	1.5	13
99	Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: A population-based study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 137-144.e1.	0.6	10
100	9. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€”2018</i>. <i>Diabetes Care</i> , 2018, 41, S86-S104.	4.3	461
101	Dynamic changes of the composition of plasma <sc>HDL</sc> particles in patients with cardiac disease: Spotlight on sphingosineâ€”phosphate/serum amyloid A ratio. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018, 45, 319-325.	0.9	3
102	Association of <i>CETP</i> Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults. <i>JAMA Cardiology</i> , 2018, 3, 34.	3.0	54
103	A translational evidence for cholesteryl ester transfer protein modulation by glucocorticoids: A time for reflection. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12856.	1.7	0
104	The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis. <i>Postgraduate Medicine</i> , 2018, 130, 129-136.	0.9	6
105	Therapeutic Intranasal Vaccine HB-ATV-8 Prevents Atherogenesis and Non-alcoholic Fatty Liver Disease in a Pig Model of Atherosclerosis. <i>Archives of Medical Research</i> , 2018, 49, 456-470.	1.5	7
106	Statin Intolerance: an Overview of the Current Status and Possible Treatment Options. <i>Journal of Lipid and Atherosclerosis</i> , 2018, 7, 77.	1.1	3
107	Cardiovascular Disease as a Result of the Interactions Between Obesity, Climate Change, and Inflammation: The COCCI Syndemic. <i>Journal of Osteopathic Medicine</i> , 2018, 118, 719-729.	0.4	3
108	Available oral lipid-lowering agents could bring most high-risk patients to target. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 485-490.	0.6	6
109	High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease. <i>Drugs in Context</i> , 2018, 7, 1-9.	1.0	129
110	New data from two CV trials result in one win, one loss. <i>Pharmacy Today</i> , 2018, 24, 22.	0.0	0
111	Low HDL and High HDL Syndromes. , 2018, , 327-339.		1
112	CETP genetic variant rs1800777 (allele A) is associated with abnormally low HDL-C levels and increased risk of AKI during sepsis. <i>Scientific Reports</i> , 2018, 8, 16764.	1.6	26

#	ARTICLE	IF	CITATIONS
113	High-Density Lipoproteinâ€œTargeted Therapiesâ€œNot Dead Yetâ€œReply. JAMA Cardiology, 2018, 3, 1255.	3.0	1
114	Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval. JACC Basic To Translational Science, 2018, 3, 690-703.	1.9	18
115	Sulfonylated Benzothiazoles as Inhibitors of Endothelial Lipase. ACS Medicinal Chemistry Letters, 2018, 9, 1263-1268.	1.3	3
116	Distinct Proteomic Signatures in 16 HDL (High-Density Lipoprotein) Subspecies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2827-2842.	1.1	75
117	Bivariate Genome-Wide Association Scan Identifies 6 Novel Loci Associated With Lipid Levels and Coronary Artery Disease. Circulation Genomic and Precision Medicine, 2018, 11, e002239.	1.6	26
119	A Mendelian randomization study of the effects of blood lipids on breast cancer risk. Nature Communications, 2018, 9, 3957.	5.8	121
120	Recent Advances in the Development of Vaccines for Diabetes, Hypertension, and Atherosclerosis. Journal of Diabetes Research, 2018, 2018, 1-8.	1.0	8
121	CETP inhibition, statins and diabetes. Atherosclerosis, 2018, 278, 143-146.	0.4	15
122	Is hypertriglyceridemia atherogenic?. Presse Medicale, 2018, 47, 757-763.	0.8	6
123	Novel approaches to lipid-lowering therapy. South African Medical Journal, 2018, 108, 262.	0.2	4
124	Cholesteryl ester transfer protein: An enigmatic pharmacology â€œ Antagonists and agonists. Atherosclerosis, 2018, 278, 286-298.	0.4	25
125	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. American Heart Journal, 2018, 206, 80-93.	1.2	276
126	Dyslipidemias in clinical practice. Clinica Chimica Acta, 2018, 487, 117-125.	0.5	26
127	Translating Evidence of HDL and Plaque Regression. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1961-1968.	1.1	25
128	Commentary on High-density Lipoprotein Versus Low-density Lipoprotein Therapy and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes by Nikolaos Papageorgiou et al.. Current Cardiology Reviews, 2018, 14, 301-302.	0.6	0
129	Recent Highlights of ATVB. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, e185-e197.	1.1	3
130	High-Intensity Versus Non-High-Intensity Statins in Patients Achieving Low-Density Lipoprotein Cholesterol Goal After Percutaneous Coronary Intervention. Journal of the American Heart Association, 2018, 7, e009517.	1.6	13
131	CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction. Expert Opinion on Investigational Drugs, 2018, 27, 997-1005.	1.9	18



#	ARTICLE	IF	CITATIONS
132	Trimethylamine N-Oxide: A Link among Diet, Gut Microbiota, Gene Regulation of Liver and Intestine Cholesterol Homeostasis and HDL Function. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3228.	1.8	138
133	Lipid management in patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2018, 14, 727-749.	4.1	153
134	Beyond Statins: Who and When to Prescribe?. <i>Current Diabetes Reports</i> , 2018, 18, 126.	1.7	4
135	COSMIC project: consensus on the objectives of the metabolic syndrome in clinic. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 683-697.	1.1	19
136	Lipids: a personal view of the past decade. <i>Hormones</i> , 2018, 17, 461-478.	0.9	5
137	CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet. <i>Diabetes</i> , 2018, 67, 2494-2506.	0.3	20
138	Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk. <i>Atherosclerosis</i> , 2018, 278, 135-142.	0.4	20
139	Should Measures of High-Density Lipoprotein Function Be Added to the Low-Density Lipoprotein Cholesterol Target Level-Based Guidelines for Prevention of Atherosclerotic Disease?. <i>Circulation Journal</i> , 2018, 82, 1251-1252.	0.7	0
140	Associations of High-Density Lipoprotein Particle and High-Density Lipoprotein Cholesterol With Alcohol Intake, Smoking, and Body Mass Indexâ€• The INTERLIPID Study â€•. <i>Circulation Journal</i> , 2018, 82, 2557-2565.	0.7	18
142	From lipid locus to drug target through human genomics. <i>Cardiovascular Research</i> , 2018, 114, 1258-1270.	1.8	17
143	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. <i>Clinical Chemistry</i> , 2018, 64, 1006-1033.	1.5	189
144	Further options for treating lipids in people with diabetes: targeting <sc>LDL</sc>â€•cholesterol and beyond. <i>Diabetic Medicine</i> , 2018, 35, 1173-1180.	1.2	3
145	Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding. <i>Journal of Lipid Research</i> , 2018, 59, 1266-1275.	2.0	62
146	CETP inhibition and HDL: what is the trial REVEALing?. <i>Cardiovascular Research</i> , 2018, 114, e15-e16.	1.8	5
147	Evolutionaire geneskunde. <i>Bijblijven (Amsterdam, Netherlands)</i> , 2018, 34, 391-425.	0.0	0
148	Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events. <i>Current Cardiology Reports</i> , 2018, 20, 55.	1.3	6
149	Mendelian randomization: Its impact on cardiovascular disease. <i>Journal of Cardiology</i> , 2018, 72, 307-313.	0.8	23
150	Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care. <i>Journal of the Endocrine Society</i> , 2018, 2, 497-512.	0.1	19

#	ARTICLE	IF	CITATIONS
151	Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 244-256.	2.3	14
152	Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy. <i>Journal of Clinical Lipidology</i> , 2018, 12, 972-980.e1.	0.6	16
153	Causal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 995-1010.	1.1	109
154	Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials. <i>Advances in Therapy</i> , 2018, 35, 899-927.	1.3	1
155	Association between high-density lipoprotein subfractions and low-grade inflammation, insulin resistance, and metabolic syndrome components: The ELSA-Brasil study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1290-1297.e1.	0.6	10
156	Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. <i>Journal of the American College of Cardiology</i> , 2018, 72, 330-343.	1.2	152
157	Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering. <i>Journal of Lipids</i> , 2018, 2018, 1-13.	1.9	23
158	High-Density Lipoproteins-Associated Proteins and Subspecies Related to Arterial Stiffness in Young Adults with Type 2 Diabetes Mellitus. <i>Complexity</i> , 2018, 2018, 1-14.	0.9	0
159	High-Density Lipoproteins and Apolipoprotein A-I Improve Stent Biocompatibility. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1691-1701.	1.1	16
160	HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?. <i>Current Cardiology Reports</i> , 2018, 20, 66.	1.3	38
161	Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels. <i>JAMA Cardiology</i> , 2018, 3, 823.	3.0	158
162	Pharmacological Intervention to Modulate HDL: What Do We Target?. <i>Frontiers in Pharmacology</i> , 2017, 8, 989.	1.6	47
163	Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1578-1585.	1.0	1
164	Hypercholesterolaemia – practical information for non-specialists. <i>Archives of Medical Science</i> , 2018, 1, 1-21.	0.4	39
165	Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management. <i>Frontiers in Pharmacology</i> , 2018, 9, 707.	1.6	31
166	Effect of Serial Infusions of CER-001, a Pre- $\beta^2$ High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial. <i>JAMA Cardiology</i> , 2018, 3, 815.	3.0	135
167	Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial. <i>JAMA Cardiology</i> , 2018, 3, 806.	3.0	129
168	Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. <i>Annals of Medicine</i> , 2018, 50, 461-484.	1.5	28

#	ARTICLE	IF	CITATIONS
169	The Evolving Future of PCSK9 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2018, 72, 314-329.	1.2	162
170	The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1680.	1.8	41
171	Unravelling HDL's "Looking beyond the Cholesterol Surface to the Quality Within. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1971.	1.8	51
172	Plasma high density lipoproteins: Therapeutic targeting and links to atherogenic inflammation. <i>Atherosclerosis</i> , 2018, 276, 39-43.	0.4	45
173	Application of Genetic Epidemiology to CETP (Cholesteryl Ester Transfer Protein) Concentration and Risk of Cardiovascular Disease. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002138.	1.6	4
175	Clinical trials. <i>Current Opinion in Lipidology</i> , 2018, 29, 277-278.	1.2	0
176	Clinical Pharmacokinetics and Pharmacodynamics of Dalceapib. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1359-1367.	1.6	8
177	CETP (Cholesteryl Ester Transfer Protein) Concentration. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002034.	1.6	44
178	Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?. <i>Current Cardiology Reports</i> , 2018, 20, 88.	1.3	18
179	A critical appraisal of the measurement of serum HDL cholesterol efflux capacity™ and its use as surrogate marker of risk of cardiovascular disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2018, 1863, 1257-1273.	1.2	18
180	The ODYSSEY Outcomes trial: Clinical implications and exploration of the limits of what can be achieved through lipid lowering. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1102-1105.	0.6	8
181	High density lipoprotein cholesterol and cancer: Marker or causative?. <i>Progress in Lipid Research</i> , 2018, 71, 54-69.	5.3	79
182	Use of guideline-recommended management in established coronary heart disease in the observational DYSIS II study. <i>International Journal of Cardiology</i> , 2018, 270, 21-27.	0.8	16
183	Determinants of Achieved LDL Cholesterol and Non-HDL Cholesterol in the Management of Dyslipidemias. <i>Current Cardiology Reports</i> , 2018, 20, 60.	1.3	8
184	Towards more specific treatment for diabetic dyslipidemia. <i>Current Opinion in Lipidology</i> , 2018, 29, 307-312.	1.2	14
185	Long-Term Prognosis of Patients With Transient Ischemic Attack or Stroke and Symptomatic Vascular Disease in Multiple Arterial Beds. <i>Stroke</i> , 2018, 49, 1639-1646.	1.0	16
186	A failure of standardization or a failure of the process of standardization. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1325-1326.	0.6	3
187	Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies. <i>JAMA Cardiology</i> , 2018, 3, 619.	3.0	428

#	ARTICLE	IF	CITATIONS
188	Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities. <i>Angiology</i> , 2019, 70, 197-209.	0.8	18
189	Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 568-581.	2.3	6
190	High-density lipoprotein function is associated with atherosclerotic burden and cardiovascular outcomes in type 2 diabetes. <i>Atherosclerosis</i> , 2019, 282, 183-187.	0.4	6
191	The HDL lipidome is widely remodeled by fast food versus Mediterranean diet in 4 days. <i>Metabolomics</i> , 2019, 15, 114.	1.4	19
193	Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. <i>Lancet, The</i> , 2019, 394, 697-708.	6.3	67
194	Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options. <i>Current Cardiology Reports</i> , 2019, 21, 110.	1.3	24
195	Modified and Dysfunctional Lipoproteins in Atherosclerosis: Effectors or Biomarkers?. <i>Current Medicinal Chemistry</i> , 2019, 26, 1512-1524.	1.2	17
196	Is high-density lipoprotein a modifiable treatment target or just a biomarker for cardiovascular disease?. <i>JRSM Cardiovascular Disease</i> , 2019, 8, 204800401986973.	0.4	3
197	Steering the Lipid Transfer To Unravel the Mechanism of Cholesteryl Ester Transfer Protein Inhibition. <i>Biochemistry</i> , 2019, 58, 3789-3801.	1.2	5
198	Association of extremely high levels of high-density lipoprotein cholesterol with endothelial dysfunction in men. <i>Journal of Clinical Lipidology</i> , 2019, 13, 664-672.e1.	0.6	18
199	Diabetes and Atherogenic Dyslipidemia. , 2019, , 587-596.		3
200	Repeated measures of extremely high levels of high-density lipoprotein cholesterol and subsequent all-cause mortality and cardiovascular events: A longitudinal study. <i>Atherosclerosis</i> , 2019, 288, 17-25.	0.4	11
201	HDL Cholesterol as a Marker of Disease Severity and Prognosis in Patients with Pulmonary Arterial Hypertension. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3514.	1.8	17
202	Impact of <i>ADCY9</i> Genotype on Response to Anacetrapib. <i>Circulation</i> , 2019, 140, 891-898.	1.6	34
203	Targeting cellular cholesterol for anticancer therapy. <i>FEBS Journal</i> , 2019, 286, 4192-4208.	2.2	39
204	Rounding the corner on residual risk: Implications of REDUCE <sup>IT</sup> for omega-3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease. <i>Clinical Cardiology</i> , 2019, 42, 829-838.	0.7	13
205	Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 38.	0.4	1
206	Lipoprotein Lipase Inhibitor, Nordihydroguaiaretic Acid, Aggravates Metabolic Phenotypes and Alters HDL Particle Size in the Western Diet-Fed db/db Mice. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3057.	1.8	7

#	ARTICLE	IF	CITATIONS
207	HEART UK consensus statement on Lipoprotein(a): A call to action. <i>Atherosclerosis</i> , 2019, 291, 62-70.	0.4	142
208	Lipid transfer to high-density lipoproteins in coronary artery disease patients with and without previous cerebrovascular ischemic events. <i>Clinical Cardiology</i> , 2019, 42, 1100-1105.	0.7	7
209	High-density Lipoprotein-cholesterol Subfractions and Coronary Artery Calcium: The ELSA-Brasil Study. <i>Archives of Medical Research</i> , 2019, 50, 362-367.	1.5	14
210	Implications for REDUCE IT in clinical practice. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 395-400.	1.6	12
211	Common Risk Factors and Prevention. , 2019, , 130-153.		1
212	Update of therapeutic planning tables oriented towards obtaining therapeutic objectives. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019, 31, 271-277.	0.1	3
213	Essen Risk Score in Prediction of Myocardial Infarction After Transient Ischemic Attack or Ischemic Stroke Without Prior Coronary Artery Disease. <i>Stroke</i> , 2019, 50, 3393-3399.	1.0	22
214	Apolipoprotein B Particles and Cardiovascular Disease. <i>JAMA Cardiology</i> , 2019, 4, 1287.	3.0	299
215	Highlighting Residual Atherosclerotic Cardiovascular Disease Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, e1-e9.	1.1	45
216	A new method for measuring cholesterol efflux capacity uses stable isotope-labeled, not radioactive-labeled, cholesterol. <i>Journal of Lipid Research</i> , 2019, 60, 1959-1967.	2.0	8
217	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019, 290, 140-205.	0.4	1,753
218	Lipid trafficking in cardiovascular disease. <i>Advances in Clinical Chemistry</i> , 2019, 92, 105-140.	1.8	10
219	Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis. <i>Journal of Lipid Research</i> , 2019, 60, 550-565.	2.0	26
220	Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 477-487.	1.2	102
221	What is "LDL cholesterol"™?. <i>Nature Reviews Cardiology</i> , 2019, 16, 197-198.	6.1	43
222	Lipid-Lowering Agents. <i>Circulation Research</i> , 2019, 124, 386-404.	2.0	124
223	Moving Targets. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 349-359.	1.1	31
224	Is elevated triglyceride high density lipoprotein cholesterol ratio a risk factor that causes acute coronary syndrome to appear earlier?. <i>Bratislava Medical Journal</i> , 2019, 119, 770-775.	0.4	8

#	ARTICLE	IF	CITATIONS
225	HDL cholesterol and ASCVD risk stratification: A debate. <i>Atherosclerosis</i> , 2019, 283, 7-12.	0.4	43
226	Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 547.	1.6	14
227	Hellenic Postprandial Lipemia Study (HPLS): Rationale and design of a prospective, open-label trial to determinate the prevalence of abnormal postprandial lipemia as well as its interaction with statins in patients at high- and very high-risk for cardiovascular disease. <i>Contemporary Clinical Trials</i> , 2019, 82, 101-105.	0.8	2
228	Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy. <i>Journal of Clinical Lipidology</i> , 2019, 13, 580-585.	0.6	16
229	The association of genetic variants in the cholesteryl ester transfer protein gene with hemostatic factors and a first venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1535-1543.	1.9	1
230	Cholesterol efflux capacity, HDL cholesterol, and risk of coronary heart disease: a nested case-control study in men. <i>Journal of Lipid Research</i> , 2019, 60, 1457-1464.	2.0	27
231	Intra-individual variability in high density lipoprotein cholesterol and risk of end-stage renal disease: A nationwide population-based study. <i>Atherosclerosis</i> , 2019, 286, 135-141.	0.4	10
232	Effect of Food on the Pharmacokinetics of 2 Formulations of DRL-17822, a Novel Selective Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Males. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 1042-1052.	0.8	2
233	Evacetrapib reduces pre <sup>β</sup> -1 HDL in patients with atherosclerotic cardiovascular disease or diabetes. <i>Atherosclerosis</i> , 2019, 285, 147-152.	0.4	8
234	Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations. <i>Science China Life Sciences</i> , 2019, 62, 758-770.	2.3	15
235	An updated review of lipid-modifying therapy. <i>Medical Journal of Australia</i> , 2019, 211, 87-92.	0.8	9
236	Emerging Lipid-Lowering Therapies in Secondary Prevention. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	0.8	0
237	Direct Estimation of HDL-Mediated Cholesterol Efflux Capacity from Serum. <i>Clinical Chemistry</i> , 2019, 65, 1042-1050.	1.5	17
238	Residual cardiovascular risk among people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 28-38.	2.2	31
239	The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 6-16.	2.2	13
240	Identification of biomarkers in macrophages of atherosclerosis by microarray analysis. <i>Lipids in Health and Disease</i> , 2019, 18, 107.	1.2	19
241	Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 544-554.	0.5	11
242	Diabetogenic Action of Statins: Mechanisms. <i>Current Atherosclerosis Reports</i> , 2019, 21, 23.	2.0	43

#	ARTICLE	IF	CITATIONS
243	Biology, pathophysiology and current therapies that affect lipoprotein (a) levels. Journal of Molecular and Cellular Cardiology, 2019, 131, 1-11.	0.9	24
244	Apolipoprotein A-I Protects Against Pregnancy-Induced Insulin Resistance in Rats. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1160-1171.	1.1	24
245	Using Human Genetics to Drive Drug Discovery: A Perspective. American Journal of Kidney Diseases, 2019, 74, 111-119.	2.1	7
246	Lifestyles correlate with stroke recurrence in Chinese inpatients with first-ever acute ischemic stroke. Journal of Neurology, 2019, 266, 1194-1202.	1.8	22
247	Rethinking good cholesterol: a clinicians' guide to understanding HDL. Lancet Diabetes and Endocrinology, 2019, 7, 575-582.	5.5	38
248	Genetics of Common, Complex Coronary Artery Disease. Cell, 2019, 177, 132-145.	13.5	166
249	Trials in Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk. Clinical Pharmacology and Therapeutics, 2019, 106, 960-967.	2.3	2
250	Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage – A Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 1703-1709.	0.7	31
251	Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome. Sexual Medicine Reviews, 2019, 7, 476-490.	1.5	24
252	Emerging drugs for the treatment of hypercholesterolemia. Expert Opinion on Emerging Drugs, 2019, 24, 63-69.	1.0	16
253	Statins in Ischemic Stroke Prevention: What Have We Learned in the Post-SPARCL (The Stroke) Trial? Neurology, 2019, 21, 22.	0.7	16
254	Regulatory Considerations for Early Clinical Development of Drugs for Diabetes, Obesity, Nonalcoholic Steatohepatitis (NASH) and Other Cardiometabolic Disorders. , 2019, , 487-515.		0
255	The culprit is the carrier, not the loads: cholesterol, triglycerides and apolipoprotein B in atherosclerosis and coronary heart disease. International Journal of Epidemiology, 2019, 48, 1389-1392.	0.9	37
256	Apolipoprotein A-II improves pancreatic cell function independent of the ATP-binding cassette transporters ABCA1 and ABCG1. FASEB Journal, 2019, 33, 8479-8489.	0.2	17
257	Impact of Lipoprotein (a) Levels on Long-Term Outcomes in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction. Circulation Journal, 2019, 83, 1047-1053.	0.7	11
258	Vaccination against atherosclerosis. Current Opinion in Immunology, 2019, 59, 15-24.	2.4	31
259	Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500,000 men and women in China. Lancet, 2019, 393, 1831-1842.	6.3	320
260	High-density lipoprotein lipid peroxidation as a molecular signature of the risk for developing cardiovascular disease: Results from MASHAD cohort. Journal of Cellular Physiology, 2019, 234, 16168-16177.	2.0	10



#	ARTICLE	IF	CITATIONS
261	Shotgun proteomic analysis reveals proteome alterations in HDL of patients with cholesteryl ester transfer protein deficiency. <i>Journal of Clinical Lipidology</i> , 2019, 13, 317-325.	0.6	20
262	HDL-Targeted Therapies During Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 371-381.	1.3	14
263	Management of established coronary artery disease in aircrew without myocardial infarction or revascularisation. <i>Heart</i> , 2019, 105, s25-s30.	1.2	9
264	Heuristics and Explanation in Translational Medicine. <i>Perspectives in Biology and Medicine</i> , 2019, 62, 675-689.	0.3	0
265	Effect of coexisting vascular disease on long-term risk of recurrent events after TIA or stroke. <i>Neurology</i> , 2019, 93, e695-e707.	1.5	13
267	The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits. <i>Scientific Reports</i> , 2019, 9, 16183.	1.6	2
268	Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition. <i>PLoS Biology</i> , 2019, 17, e3000572.	2.6	29
269	Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation. <i>Scientific Reports</i> , 2019, 9, 20354.	1.6	21
270	Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e013790.	1.6	3
271	Is Anacetrapib Better Than Its CETP Inhibitor Counterparts?. <i>Cardiology in Review</i> , 2019, 27, 242-248.	0.6	5
272	HDL from an Alzheimer's disease perspective. <i>Current Opinion in Lipidology</i> , 2019, 30, 224-234.	1.2	70
273	Molecular regulation of plasma lipid levels during systemic inflammation and sepsis. <i>Current Opinion in Lipidology</i> , 2019, 30, 108-116.	1.2	34
274	High-density lipoprotein or cyclodextrin extraction of cholesterol from aggregated LDL reduces foam cell formation. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	9
275	Is hypertriglyceridemia atherogenic?. <i>Current Opinion in Lipidology</i> , 2019, 30, 291-299.	1.2	11
276	Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00543.	1.1	7
277	Management of Hyperlipidemia After Stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 93.	0.4	11
278	Inheritance of high and low HDL: mechanisms and management. <i>Current Opinion in Lipidology</i> , 2019, 30, 307-313.	1.2	9
279	Cholesterol membrane content has a ubiquitous evolutionary function in immune cell activation: the role of HDL. <i>Current Opinion in Lipidology</i> , 2019, 30, 462-469.	1.2	18



#	ARTICLE	IF	CITATIONS
280	Vascular Macrophages in Atherosclerosis. <i>Journal of Immunology Research</i> , 2019, 2019, 1-14.	0.9	108
281	Cardiovascular risk reduction with icosapent ethyl. <i>Current Opinion in Cardiology</i> , 2019, 34, 721-727.	0.8	23
282	Apolipoprotein CIII and diabetes. Is there a link?. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3118.	1.7	17
283	High-Density Lipoprotein and High-Density Lipoprotein Cholesterol. , 2019, , 61-69.		1
284	Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 89-96.	1.1	91
285	Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation. <i>Current Pharmaceutical Design</i> , 2019, 24, 3638-3646.	0.9	10
286	Assessment of HDL Cholesterol Removal Capacity: Toward Clinical Application. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 111-120.	0.9	20
287	Characterization of Anacetrapib Distribution into the Lipid Droplet of Adipose Tissue in Mice and Human Cultured Adipocytes. <i>Drug Metabolism and Disposition</i> , 2019, 47, 227-233.	1.7	4
288	Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e1144-e1161.	1.6	87
289	Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile. <i>European Journal of Human Genetics</i> , 2019, 27, 422-431.	1.4	30
290	PCSK9 inhibitors: clinical evidence and implementation. <i>Nature Reviews Cardiology</i> , 2019, 16, 155-165.	6.1	195
291	Associations between risk of overall mortality, cause-specific mortality and level of inflammatory factors with extremely low and high high-density lipoprotein cholesterol levels among American adults. <i>International Journal of Cardiology</i> , 2019, 276, 242-247.	0.8	30
292	Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3210-3227.	1.2	124
293	Commentary on Fit-For-Purpose Models for Regulatory Applications. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 18-20.	1.6	14
294	Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 229-235.	1.0	0
295	HDL and cardiovascular disease. <i>Pathology</i> , 2019, 51, 142-147.	0.3	56
296	High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 177-186.	1.2	37
297	Rabbit models of human diseases for diagnostics and therapeutics development. <i>Developmental and Comparative Immunology</i> , 2019, 92, 99-104.	1.0	17

#	ARTICLE	IF	CITATIONS
298	Capitalizing on Insights from Human Genetics to Identify Novel Therapeutic Targets for Coronary Artery Disease. <i>Annual Review of Medicine</i> , 2019, 70, 19-32.	5.0	6
299	Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor. <i>Cardiology in Review</i> , 2019, 27, 49-56.	0.6	26
300	Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 854-862.	2.5	62
301	Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 533-543.	0.8	42
302	Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis. <i>Progress in Lipid Research</i> , 2019, 73, 65-91.	5.3	155
303	Limitations of hazard ratios in clinical trials. <i>European Heart Journal</i> , 2019, 40, 1378-1383.	1.0	52
304	Nonfasting versus fasting lipid profile for cardiovascular risk prediction. <i>Pathology</i> , 2019, 51, 131-141.	0.3	112
305	Impaired Vascular Redox Signaling in the Vascular Complications of Obesity and Diabetes Mellitus. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 333-353.	2.5	25
306	Critical review of 2016 ACC guidelines on therapies for cholesterol lowering with reference to laboratory testing. <i>Clinica Chimica Acta</i> , 2019, 489, 189-195.	0.5	4
307	Recent advances in synthetic pharmacotherapies for dyslipidaemias. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1576-1596.	0.8	24
308	Statins increase Lp(a) plasma level: is this clinically relevant?. <i>European Heart Journal</i> , 2020, 41, 2285-2287.	1.0	14
309	A Low-Cost On-Chip Built-In Self-Test Solution for ADC Linearity Test. <i>IEEE Transactions on Instrumentation and Measurement</i> , 2020, 69, 3516-3526.	2.4	12
310	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	1.0	4,871
311	Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1255-1268.	0.8	33
312	Causal Inference for Genetically Determined Levels of High-Density Lipoprotein Cholesterol and Risk of Infectious Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 267-278.	1.1	78
313	Elevated Cholesteryl Ester Transfer Protein Activity Early in Pregnancy Predicts Prediabetes 5 Years Later. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 854-865.	1.8	1
314	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 133-144.	1.2	296
315	Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease. <i>Drugs</i> , 2020, 80, 229-239.	4.9	21

#	ARTICLE	IF	CITATIONS
316	Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene. <i>Lipids in Health and Disease</i> , 2020, 19, 3.	1.2	16
317	Eligibility and Preventive Potential for New Evidence-Based Cardiovascular Drugs in Secondary Prevention. <i>JAMA Cardiology</i> , 2020, 5, 209.	3.0	19
318	Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical considerations. , 2020, 207, 107459.		7
319	Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. <i>American Heart Journal</i> , 2020, 221, 60-66.	1.2	5
320	Endovascular Aneurysm Sealing is Associated with Higher Medium-Term Survival than Traditional EVAR. <i>Annals of Vascular Surgery</i> , 2020, 63, 145-154.	0.4	10
321	Synthesis, biological evaluation and SAR studies of ursolic acid 3 <sup>1</sup> -ester derivatives as novel CETP inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126824.	1.0	6
322	Reduced CETP glycosylation and activity in patients with homozygous B4GALT1 mutations. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 611-617.	1.7	8
323	Genetic disorders of lipoprotein metabolism. , 2020, , 245-265.		0
324	Apolipoprotein B discordance with low-density lipoprotein cholesterol and non-“high-density lipoprotein cholesterol in relation to coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). <i>Journal of Clinical Lipidology</i> , 2020, 14, 109-121.e5.	0.6	23
325	Streamlined mail-based methods for large randomised trials: lessons learnt from the ASCEND study. <i>Diabetologia</i> , 2020, 63, 898-905.	2.9	3
326	Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities. <i>Journal of Internal Medicine</i> , 2020, 287, 2-18.	2.7	74
327	Role of High-Density Lipoproteins in Cholesterol Homeostasis and Glycemic Control. <i>Journal of the American Heart Association</i> , 2020, 9, e013531.	1.6	27
328	Current Concepts in Management of Lipid Abnormalities in Patients With Coronary Artery Disease. <i>Indian Journal of Clinical Cardiology</i> , 2020, 1, 164-173.	0.3	0
329	Gymnaster Koraiensis Extract Alleviated Metabolic Syndrome Symptoms and Stimulated UCP1-Independent Energy Consumption via AMPK Activation in White Adipose Tissue. <i>Molecular Nutrition and Food Research</i> , 2020, 64, 2000490.	1.5	3
330	Interaction between high-density lipoproteins and inflammation: Function matters more than concentration!. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 94-119.	6.6	50
331	Statins in primary prevention: is the enthusiasm justified?. <i>Indian Heart Journal</i> , 2020, 72, 221-224.	0.2	0
332	Lipid-lowering treatment and low-density lipoprotein cholesterol target achievement in patients with type 2 diabetes and acute coronary syndrome. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 617-629.	0.7	3
333	Hydroxytyrosol Plays Antiatherosclerotic Effects through Regulating Lipid Metabolism via Inhibiting the p38 Signal Pathway. <i>BioMed Research International</i> , 2020, 2020, 1-12.	0.9	11

#	ARTICLE	IF	CITATIONS
334	Lipids and Lipoproteins in 2020. JAMA - Journal of the American Medical Association, 2020, 324, 595.	3.8	73
335	Bias and Loss to Follow-Up in Cardiovascular Randomized Trials: A Systematic Review. Journal of the American Heart Association, 2020, 9, e015361.	1.6	7
336	AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients. Cell Reports Medicine, 2020, 1, 100057.	3.3	72
337	Novel Insights From Human Studies on the Role of High-Density Lipoprotein in Mortality and Noncardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 128-140.	1.1	30
338	Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial. Journal of the American Heart Association, 2020, 9, e018136.	1.6	17
339	Vaccination in Atherosclerosis. Cells, 2020, 9, 2560.	1.8	24
340	Risk factors for cardiovascular disease in the Chinese population: recent progress and implications. Global Health Journal (Amsterdam, Netherlands), 2020, 4, 65-71.	1.9	9
341	Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies. Journal of the American Heart Association, 2020, 9, e016506.	1.6	8
342	The Impact of Dietary Glycemic Index and Glycemic Load on Postprandial Lipid Kinetics, Dyslipidemia and Cardiovascular Risk. Nutrients, 2020, 12, 2204.	1.7	12
343	Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Advanced Drug Delivery Reviews, 2020, 159, 4-33.	6.6	113
344	Genetics of extreme human longevity to guide drug discovery for healthy ageing. Nature Metabolism, 2020, 2, 663-672.	5.1	32
345	&lt;p>&lt;U-Shape Association of High-Density Lipoprotein Cholesterol with All-Cause and Cardiovascular Mortality in Hypertensive Population&lt;p>. Risk Management and Healthcare Policy, 2020, Volume 13, 2013-2025.	1.2	9
346	Novel LCAT (Lecithin:Cholesterol Acyltransferase) Activator DS-8190a Prevents the Progression of Plaque Accumulation in Atherosclerosis Models. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 360-376.	1.1	10
347	Cholesteryl ester transfer protein inhibitors in precision medicine. Clinica Chimica Acta, 2020, 510, 733-740.	0.5	4
348	CETP inhibition in the REVEAL trial: could we aim higher?. Archives of Medical Science, 2020, 16, 1229-1230.	0.4	1
349	Recent advances and emerging therapies in management of dyslipidemias. Trends in Cardiovascular Medicine, 2021, 31, 419-424.	2.3	3
350	Polygenic modelling of treatment effect heterogeneity. Genetic Epidemiology, 2020, 44, 868-879.	0.6	6
351	Diabetes Impairs Cellular Cholesterol Efflux From ABCA1 to Small HDL Particles. Circulation Research, 2020, 127, 1198-1210.	2.0	41

#	ARTICLE	IF	CITATIONS
352	Prevention of Stroke by Lowering Blood Cholesterol Concentrations. , 2020, , 297-307.		0
353	Tackling cardiometabolic risk in the Asia Pacific region. American Journal of Preventive Cardiology, 2020, 4, 100096.	1.3	5
354	Novel emerging therapies in atherosclerosis targeting lipid metabolism. Expert Opinion on Investigational Drugs, 2020, 29, 611-622.	1.9	36
355	Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction. JAMA Cardiology, 2020, 5, 787.	3.0	23
356	Meta-analysis of cardiovascular superiority trials published in the New England Journal of Medicine to elucidate the concept of superiority margin. Postgraduate Medical Journal, 2021, 97, 227-233.	0.9	0
357	The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Frontiers in Cardiovascular Medicine, 2020, 7, 88.	1.1	82
358	Lipid efflux mechanisms, relation to disease and potential therapeutic aspects. Advanced Drug Delivery Reviews, 2020, 159, 54-93.	6.6	18
359	Reducing residual cardiovascular risk with novel therapies. Current Opinion in Lipidology, 2020, 31, 108-110.	1.2	7
360	Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets. Current Cardiology Reports, 2020, 22, 66.	1.3	26
361	Metabolic and Pharmaceutical Aspects of Fluorinated Compounds. Journal of Medicinal Chemistry, 2020, 63, 6315-6386.	2.9	358
362	Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cardiology, 2020, 145, 236-250.	0.6	33
363	Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial. BMJ Open Diabetes Research and Care, 2020, 8, e000943.	1.2	15
364	Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review. Advances in Therapy, 2020, 37, 1724-1736.	1.3	32
365	Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis. PLoS Medicine, 2020, 17, e1003062.	3.9	470
366	The mystery of evacetrapib - why are CETP inhibitors failing?. Expert Review of Cardiovascular Therapy, 2020, 18, 127-130.	0.6	12
367	Coronary Artery Disease: Therapeutics and Drug Discovery. Advances in Experimental Medicine and Biology, 2020, , .	0.8	4
368	Pharmacokinetics of current and emerging treatments for hypercholesterolemia. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 371-385.	1.5	9
369	Low cholesterol syndrome and drug development. Current Opinion in Cardiology, 2020, 35, 423-427.	0.8	1

#	ARTICLE	IF	CITATIONS
370	HDL cholesterol and apolipoprotein A-I concentrations and risk of atherosclerotic cardiovascular disease: Human genetics to unravel causality. <i>Atherosclerosis</i> , 2020, 299, 53-55.	0.4	12
371	The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232092456.	1.1	8
372	Symptomatic and asymptomatic intracranial atherosclerotic stenosis: 3 yearsâ€™ prospective study. <i>Journal of Neurology</i> , 2020, 267, 1687-1698.	1.8	9
373	The Magic of Randomization versus the Myth of Real-World Evidence. <i>New England Journal of Medicine</i> , 2020, 382, 674-678.	13.9	296
374	Atherosclerosis: Insights into Vascular Pathobiology and Outlook to Novel Treatments. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 744-757.	1.1	41
375	Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. <i>American Heart Journal</i> , 2020, 222, 157-165.	1.2	21
376	Apolipoprotein A-I concentrations and risk of coronary artery disease: A Mendelian randomization study. <i>Atherosclerosis</i> , 2020, 299, 56-63.	0.4	47
377	Genetic determinants of blood lipids and cerebral small vessel disease: role of high-density lipoprotein cholesterol. <i>Brain</i> , 2020, 143, 597-610.	3.7	51
378	Lower LDL is better â€” can this be achieved with CETP inhibition therapy?. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 1-5.	0.6	6
379	Association of cholesterol uptake capacity, a novel indicator for HDL functionality, and coronary plaque properties: An optical coherence tomography-based observational study. <i>Clinica Chimica Acta</i> , 2020, 503, 136-144.	0.5	10
380	Roles of Reconstituted High-Density Lipoprotein Nanoparticles in Cardiovascular Disease: A New Paradigm for Drug Discovery. <i>International Journal of Molecular Sciences</i> , 2020, 21, 739.	1.8	20
381	A robust and efficient method for Mendelian randomization with hundreds of genetic variants. <i>Nature Communications</i> , 2020, 11, 376.	5.8	290
382	The Rise and Fall of the HDL Hypothesis. <i>Drugs</i> , 2020, 80, 353-362.	4.9	7
383	Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. <i>Diabetes Care</i> , 2020, 43, 1077-1084.	4.3	21
384	Low-Density Lipoprotein Cholesterol Level cannot be too Low: Considerations from Clinical Trials, Human Genetics, and Biology. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 489-498.	0.9	14
385	Bariatric Surgery Improves HDL Function Examined by ApoA1 Exchange Rate and Cholesterol Efflux Capacity in Patients with Obesity and Type 2 Diabetes. <i>Biomolecules</i> , 2020, 10, 551.	1.8	27
386	Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). <i>European Heart Journal</i> , 2020, 41, 2262-2271.	1.0	65
387	High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 39.	1.1	52

#	ARTICLE	IF	CITATIONS
388	Correlation without a cause: an epidemiological odyssey. <i>International Journal of Epidemiology</i> , 2020, 49, 4-14.	0.9	45
389	HDL-C is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose-response fashion: a pooled analysis of 37 prospective cohort studies. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1187-1203.	0.8	72
390	Probuco Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE). <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 103-123.	0.9	26
391	HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 166-173.	0.8	26
392	Cholesteryl Ester Transfer Protein Impairs Triglyceride Clearance via Androgen Receptor in Male Mice. <i>Lipids</i> , 2021, 56, 17-29.	0.7	7
393	HDL in Morbidity and Mortality: A 40+ Year Perspective. <i>Clinical Chemistry</i> , 2021, 67, 19-23.	1.5	13
394	Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis. <i>Circulation</i> , 2021, 143, 921-934.	1.6	55
395	Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition. <i>Annual Review of Medicine</i> , 2021, 72, 447-458.	5.0	12
396	LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies. <i>Seminars in Cancer Biology</i> , 2021, 73, 134-157.	4.3	30
397	Effects of bariatric surgery on lipid-lipoprotein profile. <i>Metabolism: Clinical and Experimental</i> , 2021, 115, 154441.	1.5	14
398	Novel role of cholesteryl ester transfer protein (CETP): attenuation of adiposity by enhancing lipolysis and brown adipose tissue activity. <i>Metabolism: Clinical and Experimental</i> , 2021, 114, 154429.	1.5	8
399	Cholesteryl ester transfer protein (CETP) inhibitors based on cyclic urea, bicyclic urea and bicyclic sulfamide cores. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 32, 127668.	1.0	6
400	The loss-of-function mutation of CETP affects HDLc levels but not ApoA1 in patients with acute myocardial infarction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 602-607.	1.1	6
401	Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 255-265.	1.0	8
402	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 49-56.	2.3	12
403	Learning by experience. , 2021, , 455-462.		0
404	Integrated Analysis of Two Probuco Trials for the Secondary Prevention of Atherosclerotic Cardiovascular Events: PROSPECTIVE and IMPACT. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 850-865.	0.9	5
405	Cardiovascular Disease Epidemiology and Risk Factors: General Concepts. <i>Contemporary Cardiology</i> , 2021, , 1-22.	0.0	0



#	ARTICLE	IF	CITATIONS
406	Serum HDL-Cholesterol Level Does Not Influence Cardiovascular Event Rate under Sufficient Lowering of LDL-Cholesterol by Pitavastatin in Patients with Stable Coronary Artery Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 8-10.	0.9	0
407	The Presence of Cholesteryl Ester Transfer Protein (CETP) in Endothelial Cells Generates Vascular Oxidative Stress and Endothelial Dysfunction. <i>Biomolecules</i> , 2021, 11, 69.	1.8	11
408	Lipid-Lowering Drugs. , 2021, , 1-8.		0
409	Atherogenic dyslipidaemia and cardiovascular events in patients with diabetes or pre-diabetes and stable coronary artery disease: a prospective, cohort study. <i>BMJ Open</i> , 2021, 11, e037340.	0.8	2
410	Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1-13.	0.4	5
411	Trans-Ethnic Mendelian Randomization Study Reveals Causal Relationships Between Cardiometabolic Factors and Chronic Kidney Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
412	Plasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study. <i>Diabetologia</i> , 2021, 64, 668-680.	2.9	12
413	Recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results and phase 2b design. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	1.4	11
414	(r)HDL in theranostics: how do we apply HDL's biology for precision medicine in atherosclerosis management?. <i>Biomaterials Science</i> , 2021, 9, 3185-3208.	2.6	5
415	Cholesterol metabolism and tumor. <i>Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences</i> , 2021, 50, 23-31.	0.1	5
416	The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 85-99.	1.4	23
417	Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. <i>Nature Reviews Cardiology</i> , 2021, 18, 435-453.	6.1	88
419	Aortic valvular stenosis: Novel therapeutic strategies. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13527.	1.7	4
420	The Association between HDL-C and Subclinical Atherosclerosis Depends on CETP Plasma Concentration: Insights from the IMPROVE Study. <i>Biomedicines</i> , 2021, 9, 286.	1.4	7
421	Atherosclerosis Regression and Cholesterol Efflux in Hypertriglyceridemic Mice. <i>Circulation Research</i> , 2021, 128, 690-705.	2.0	18
422	Genetic Risk Stratification. <i>JACC Basic To Translational Science</i> , 2021, 6, 287-304.	1.9	19
423	Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome. <i>Current Atherosclerosis Reports</i> , 2021, 23, 16.	2.0	6
424	New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1564-1575.	1.2	49



#	ARTICLE	IF	CITATIONS
425	Peculiar Paradoxical Results That Puzzle Me. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1698-1699.	1.2	3
426	LDL-C Levels Below 55 mg/dl and Risk of Hemorrhagic Stroke: A Meta-Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105655.	0.7	9
427	Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics. <i>Cardiovascular Research</i> , 2022, 118, 1218-1231.	1.8	30
428	Large HDL2 combined with inflammatory factors as superior predictors for coronary artery disease than small HDL3. <i>Annals of Translational Medicine</i> , 2021, 9, 672-672.	0.7	1
429	HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4547.	1.8	28
430	ANGPTL8 protein-truncating variant associated with lower serum triglycerides and risk of coronary disease. <i>PLoS Genetics</i> , 2021, 17, e1009501.	1.5	28
431	Umbrella Review on Non-Statin Lipid-Lowering Therapy. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 107424842110029.	1.0	11
432	Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trial. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	16
433	Different Approaches in Therapy Aiming to Stabilize an Unstable Atherosclerotic Plaque. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4354.	1.8	10
434	High-density lipoproteins, reverse cholesterol transport and atherogenesis. <i>Nature Reviews Cardiology</i> , 2021, 18, 712-723.	6.1	91
435	A New Equation Based on the Standard Lipid Panel for Calculating Small Dense Low-Density Lipoprotein-Cholesterol and Its Use as a Risk-Enhancer Test. <i>Clinical Chemistry</i> , 2021, 67, 987-997.	1.5	39
436	High Density Lipoproteins and Diabetes. <i>Cells</i> , 2021, 10, 850.	1.8	34
437	Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003219.	1.6	4
438	Targeting HDL in tumor microenvironment: New hope for cancer therapy. <i>Journal of Cellular Physiology</i> , 2021, 236, 7853-7873.	2.0	15
440	Plasma high-density lipoprotein cholesterol and risk of dementia: observational and genetic studies. <i>Cardiovascular Research</i> , 2022, 118, 1330-1343.	1.8	24
441	Safety and Efficacy of Evacetrapib in Patients with Inadequately-controlled Hypercholesterolemia and High Cardiovascular Risk; A meta-analysis of Randomized Placebo-controlled Trials. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2021, 168, 102282.	1.0	0
442	High-Density Lipoprotein Anti-Inflammatory Capacity and Incident Cardiovascular Events. <i>Circulation</i> , 2021, 143, 1935-1945.	1.6	67
444	Dysfunctional High-Density Lipoproteins in Type 2 Diabetes Mellitus: Molecular Mechanisms and Therapeutic Implications. <i>Journal of Clinical Medicine</i> , 2021, 10, 2233.	1.0	15

#	ARTICLE	IF	CITATIONS
445	Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, 815-834.	0.6	11
446	Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects. <i>Advances in Therapy</i> , 2021, 38, 3973-3985.	1.3	0
447	Cholesterol efflux pathways, inflammation, and atherosclerosis. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2021, 56, 426-439.	2.3	63
448	Cognition, Statins, and Cholesterol in Elderly Ischemic Stroke Patients: A Neurologist's Perspective. <i>Medicina (Lithuania)</i> , 2021, 57, 616.	0.8	8
449	Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2330-2341.	1.1	14
450	The TIMI Study Group's Contributions to the Advancement of Cardiology -With Focus on Atherosclerotic Cardiovascular Disease-. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 563-572.	0.9	1
451	Mental health is correlated with lipoprotein(a) levels in male patients with premature coronary heart disease. <i>Annals of Palliative Medicine</i> , 2021, 10, 6482-6492.	0.5	6
452	Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 107424842110236.	1.0	4
453	Managing dyslipidemia in patients with Type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2221-2234.	0.9	14
454	Dyslipidemia: Current Perspectives and Implications for Clinical Practice. , 0, , .		0
455	Environmental Factors Modifying HDL Functionality. <i>Current Medicinal Chemistry</i> , 2022, 29, 1687-1701.	1.2	1
456	HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role. <i>Cells</i> , 2021, 10, 1869.	1.8	46
457	MEDI6012: Recombinant Human Lecithin Cholesterol Acyltransferase, High-Density Lipoprotein, and Low-Density Lipoprotein Receptor-Mediated Reverse Cholesterol Transport. <i>Journal of the American Heart Association</i> , 2021, 10, e014572.	1.6	18
458	Comparison of the Efficacy and Safety of Atorvastatin 40 mg/3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Randomized, Double-blind Phase III Study. <i>Clinical Therapeutics</i> , 2021, 43, 1419-1430.	1.1	3
459	High-Density Lipoprotein Subfractions: Much Ado about Nothing or Clinically Important?. <i>Biomedicines</i> , 2021, 9, 836.	1.4	9
460	Association of Kidney Function With NMR-Quantified Lipids, Lipoproteins, and Metabolic Measures in Mexican Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2828-2839.	1.8	10
461	Lipoprotein (a): When to Measure and How to Treat?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 51.	2.0	18
462	Pathophysiology and inhibition of cholesteryl ester transfer protein for prevention of cardiovascular diseases: An update. <i>Drug Discovery Today</i> , 2021, 26, 1759-1764.	3.2	10

#	ARTICLE	IF	CITATIONS
463	Unraveling the Complexity of HDL Remodeling: On the Hunt to Restore HDL Quality. <i>Biomedicines</i> , 2021, 9, 805.	1.4	5
464	Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13215-13258.	2.9	10
466	Is a High HDL-Cholesterol Level Always Beneficial?. <i>Biomedicines</i> , 2021, 9, 1083.	1.4	22
467	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	1.0	2,517
468	Vexed causal inferences in nutritional epidemiologyâ€™ call for genetic help. <i>International Journal of Epidemiology</i> , 2021, , .	0.9	5
469	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1129-1150.	0.8	367
470	Synthesis and Molecular Modeling of Novel 3,5-Bis(trifluoromethyl) benzylamino Benzamides as Potential CETP Inhibitors. <i>Medicinal Chemistry</i> , 2022, 18, 417-426.	0.7	2
471	Nuevos hipolipemiantes. <i>EMC - Tratado De Medicina</i> , 2021, , .	0.0	0
472	Inflammation Alters Relationship Between Highâ€™Density Lipoprotein Cholesterol and Cardiovascular Risk in Patients With Chronic Kidney Disease: Results From KNOWâ€™CKD. <i>Journal of the American Heart Association</i> , 2021, 10, e021731.	1.6	9
473	Multitrait GWAS to connect disease variants and biological mechanisms. <i>PLoS Genetics</i> , 2021, 17, e1009713.	1.5	16
474	Apt interpretation of comprehensive lipoprotein data in large-scale epidemiology: disclosure of fundamental structural and metabolic relationships. <i>International Journal of Epidemiology</i> , 2022, 51, 996-1011.	0.9	21
475	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 5-115.	0.8	220
476	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategiesâ€™ a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021, 42, 4791-4806.	1.0	303
478	Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 141-155.	1.0	10
479	Toward a Best-in-Class Inhibitor of Cholesteryl Ester Transfer Protein (CETP). <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13212-13214.	2.9	3
481	Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARâ€™ Modulator, Pemaafibrate. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 974-996.	0.9	10
482	Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases. <i>Biomedicines</i> , 2021, 9, 1271.	1.4	18
483	Drug discovery and development: An overview of modern methods and principles. , 2021, , 1-41.		0

#	ARTICLE	IF	CITATIONS
484	Apolipoprotein A-I Mimetics for Treatment of the Residual Risk of Cardiovascular Disease. <i>Cardiometabolic Syndrome Journal</i> , 2021, 1, 135.	1.0	0
485	Trans-ethnic Mendelian-randomization study reveals causal relationships between cardiometabolic factors and chronic kidney disease. <i>International Journal of Epidemiology</i> , 2022, 50, 1995-2010.	0.9	39
486	High HDL-Cholesterol Paradox: SCARB1-LAG3-HDL Axis. <i>Current Atherosclerosis Reports</i> , 2021, 23, 5.	2.0	23
487	Genetic Variation in Sodium-glucose Cotransporter 2 and Heart Failure. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 149-158.	2.3	11
488	Cholesteryl Ester Transfer Protein and Lipid Metabolism and Cardiovascular Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1276, 15-25.	0.8	13
489	Trans Fatty Acids and Heart Health. , 2019, , .		2
490	Actualizaci3n de las tablas de planificaci3n terap3utica hipocolesterolemia orientadas a la obtenci3n de los objetivos terap3uticos. <i>Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2019, 31, 271-277.	0.4	13
491	A Novel Role for CETP as Immunological Gatekeeper: Raising HDL to Cure Sepsis?. <i>Trends in Endocrinology and Metabolism</i> , 2020, 31, 334-343.	3.1	22
492	Apolipoprotein B: the Rosetta Stone of lipidology. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 90-96.	1.2	10
493	Polygenic scores for dyslipidemia: the emerging genomic model of plasma lipoprotein trait inheritance. <i>Current Opinion in Lipidology</i> , 2021, 32, 103-111.	1.2	11
503	Particle number analysis of lipoprotein subclasses by gel permeation HPLC in patients with cholesteryl ester transfer protein deficiency. <i>PLoS ONE</i> , 2018, 13, e0190875.	1.1	11
504	HDL and Reverse Cholesterol Transport Biomarkers. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 39.	0.5	19
505	Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 171.	0.5	39
506	Cardiovascular outcomes trials with non-statin lipid-lowering drugs in diabetes. <i>British Journal of Diabetes</i> , 2018, 18, 101-105.	0.1	4
507	Everything in Moderation: Investigating the U-Shaped Link Between HDL Cholesterol and Adverse Outcomes. <i>US Cardiology Review</i> , 2019, 13, 49-53.	0.5	6
508	LDL-C plays a causal role on T2DM: a Mendelian randomization analysis. <i>Aging</i> , 2020, 12, 2584-2594.	1.4	14
509	HDL Dysfunction Caused by Mutations in apoA-I and Other Genes that are Critical for HDL Biogenesis and Remodeling. <i>Current Medicinal Chemistry</i> , 2019, 26, 1544-1575.	1.2	13
510	Biological Consequences of Dysfunctional HDL. <i>Current Medicinal Chemistry</i> , 2019, 26, 1644-1664.	1.2	65

#	ARTICLE	IF	CITATIONS
511	Cardioprotective Properties of HDL: Structural and Functional Considerations. <i>Current Medicinal Chemistry</i> , 2020, 27, 2964-2978.	1.2	19
512	Diabetes and Vascular Disease: Is It All About Glycemia?. <i>Current Pharmaceutical Design</i> , 2019, 25, 3112-3127.	0.9	14
513	A Journey through Genetic Architecture and Predisposition of Coronary Artery Disease. <i>Current Genomics</i> , 2020, 21, 382-398.	0.7	3
514	Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects. <i>Current Vascular Pharmacology</i> , 2019, 17, 332-340.	0.8	6
515	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. <i>Current Vascular Pharmacology</i> , 2019, 17, 498-514.	0.8	38
516	REVEAL study: Reveals the limitations of cholesteryl ester transfer protein inhibition. <i>Indian Journal of Endocrinology and Metabolism</i> , 2018, 22, 296.	0.2	1
517	Residual Cardiovascular Risk—Is Inflammation the Primary Cause?. <i>World Journal of Cardiovascular Diseases</i> , 2018, 08, 59-69.	0.0	4
518	Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. <i>Nature Communications</i> , 2021, 12, 5640.	5.8	57
520	Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target. <i>Metabolites</i> , 2021, 11, 690.	1.3	95
521	Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial Cohort. <i>Value in Health</i> , 2022, 25, 435-442.	0.1	4
522	Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1499-1507.	1.2	22
523	Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study. <i>Frontiers in Nutrition</i> , 2021, 8, 755834.	1.6	6
524	Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics. <i>Nature Communications</i> , 2021, 12, 6120.	5.8	13
525	Residual Cardiovascular Risk Factors in Dyslipidemia. , 0, , .		0
526	Low density lipoprotein cholesterol is associated with increased risk of cardiovascular disease in participants over 70 years old: A prospective cohort study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 447-455.	1.1	1
527	Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies. <i>Cells</i> , 2021, 10, 2832.	1.8	66
528	Factors Influencing Stent Failure in Chronic Total Occlusion Coronary Intervention. <i>Interventional Cardiology Review</i> , 2021, 16, e27.	0.7	5
529	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.	1.2	42

#	ARTICLE	IF	CITATIONS
531	Long-term Benefits and Harms Associated With Genetic Cholesteryl Ester Transfer Protein Deficiency in the General Population. <i>JAMA Cardiology</i> , 2022, 7, 55.	3.0	27
532	Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1831-1843.	1.2	32
534	Lipidsenkende Mittel. , 2018, , 577-586.		0
535	What Do We Get from Recent Statin and CETP Inhibitors Trials?. <i>Journal of Lipid and Atherosclerosis</i> , 2018, 7, 12.	1.1	1
537	4. Management of Disorders of Lipoprotein Metabolism-Update-. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2018, 107, 453-457.	0.0	0
538	NEW DRUGS FOR THE TREATMENT OF DYSLIPIDEMIA. <i>Acta Medica Medianae</i> , 2018, 57, 54-63.	0.0	0
539	The year in cardiology 2017: prevention. <i>Cardiologia Croatica</i> , 2018, 13, 79-98.	0.0	0
541	Triglyceride and high density lipoprotein metabolism in diabetes. <i>Journal of Diabetes, Metabolic Disorders &amp; Control</i> , 2018, 5, 158-165.	0.2	0
542	New clinical and pharmacological aspects of the use of atorvastatin for primary and secondary prevention of complications of cardiovascular diseases. <i>Meditinskiy Sovet</i> , 2018, , 110-117.	0.1	0
544	"The higher the better" seems to be no longer true for HDL-cholesterol. <i>Vnitri Lekarstvi</i> , 2018, 64, 1153-1155.	0.1	0
545	Encouragement of Super-aggressive LDL-lowering Therapies. <i>Journal of Coronary Artery Disease</i> , 2019, 25, 84-89.	0.1	0
548	Cholesteryl ester transfer protein: the physiological and molecular characteristics in the pathogenesis of atherosclerosis and Alzheimer's disease. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2019, 73, 387-396.	0.1	0
549	Drug Discovery for Coronary Artery Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1177, 297-339.	0.8	6
551	Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk. <i>Contemporary Cardiology</i> , 2021, , 139-158.	0.0	2
552	Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis. <i>Contemporary Cardiology</i> , 2021, , 615-636.	0.0	0
553	High-Density Lipoproteins. <i>Contemporary Cardiology</i> , 2021, , 341-361.	0.0	1
554	The Low-Density Lipoprotein Cholesterol Hypothesis: An Update. <i>Contemporary Cardiology</i> , 2021, , 121-138.	0.0	0
555	Linear reverse risk of HDL-C levels for predicting cardiovascular disease: it is not that straightforward!. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 2055-2057.	0.8	3

#	ARTICLE	IF	CITATIONS
556	How ApoB Measurements Could Improve Prevention of Cardiovascular Disease. <i>Contemporary Cardiology</i> , 2021, , 545-563.	0.0	0
557	Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease. <i>Global Cardiology Science &amp; Practice</i> , 2020, 2020, e202039.	0.3	2
558	Biomarkers in drug development. , 2022, , 323-342.		3
559	High-density lipoproteins (HDL): Novel function and therapeutic applications. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2022, 1867, 159058.	1.2	17
560	HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease – Insights from randomized clinical trials and human genetics. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2022, 1867, 159063.	1.2	19
561	Altered lipid metabolism and serum lipids in chronic kidney disease. , 2022, , 43-60.		2
562	Hypercholesterolemia and Dyslipidemia. , 2020, , 1-23.		0
564	Changes in High-Density Lipoprotein Cholesterol and Risks of Cardiovascular Events: A Post Hoc Analysis from the PICASSO Trial. <i>Journal of Stroke</i> , 2020, 22, 108-118.	1.4	3
565	Discovery and Commercial Development of Cholesteryl Transfer Protein Inhibitor Evacetrapib. <i>ACS Symposium Series</i> , 2020, , 339-372.	0.5	1
566	Genetic Disorders of Lipoprotein Metabolism: Diagnosis and Management. , 2020, , 387-411.		0
568	High density lipoprotein in atherosclerosis and coronary heart disease: Where do we stand today?. <i>Vascular Pharmacology</i> , 2021, 141, 106928.	1.0	7
569	Proteomic studies on apoB-containing lipoprotein in cardiovascular research: A comprehensive review. <i>Mass Spectrometry Reviews</i> , 2023, 42, 1397-1423.	2.8	3
574	Primary Prevention of Coronary Artery Disease. , 2021, , 81-123.		0
575	Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients. <i>Acta Cardiologica Sinica</i> , 2018, 34, 371-378.	0.1	12
577	Lipoprotein(a) Elevation: A New Diagnostic Code with Relevance to Service Members and Veterans. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2019, 36, S19-S31.	0.6	0
578	Influencing factors of coronary artery stenosis in patients with stable coronary heart disease and a correlation analysis. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 9522-9529.	0.0	1
579	Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?. <i>Cardiovascular Research</i> , 2022, 118, 2919-2931.	1.8	31
580	Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Soci�t� Francophone d� Ath�roscl�rose (NSFA). <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 828-847.	0.7	9



#	ARTICLE	IF	CITATIONS
581	The dawn of a new era of targeted lipid-lowering therapies. <i>European Heart Journal</i> , 2022, 43, 3198-3208.	1.0	48
582	Lipid-Lowering Drugs. , 2021, , 929-936.		0
583	Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. <i>European Heart Journal</i> , 2022, , .	1.0	1
584	Coronary Atherosclerotic Plaque Regression. <i>Journal of the American College of Cardiology</i> , 2022, 79, 66-82.	1.2	44
585	High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?. <i>Handbook of Experimental Pharmacology</i> , 2021, , 157-200.	0.9	3
586	Lipoprotein(a). <i>Handbook of Experimental Pharmacology</i> , 2021, , 201-232.	0.9	22
587	Very High High-Density Lipoprotein Cholesterol Levels and Cardiovascular Mortality. <i>American Journal of Cardiology</i> , 2022, 167, 43-53.	0.7	21
588	Expressing the Human Cholesteryl Ester Transfer Protein Minigene Improves Diet-Induced Fatty Liver and Insulin Resistance in Female Mice. <i>Frontiers in Physiology</i> , 2021, 12, 799096.	1.3	4
589	Addressing dyslipidemic risk beyond LDL-cholesterol. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	51
590	Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease. <i>American Journal of the Medical Sciences</i> , 2022, , .	0.4	1
591	HDL Is Not Dead Yet. <i>Biomedicines</i> , 2022, 10, 128.	1.4	8
592	Impact of Lipoprotein(a) as a Residual Risk Factor in Long-Term Cardiovascular Outcomes in Patients With Acute Coronary Syndrome Treated With Statins. <i>American Journal of Cardiology</i> , 2022, 168, 11-16.	0.7	10
593	Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Heart Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 227-237.	1.1	21
594	What is the Optimal Low-Density Lipoprotein Cholesterol?. <i>Medical Clinics of North America</i> , 2022, 106, 285-298.	1.1	2
595	LCAT- targeted therapies: Progress, failures and future. <i>Biomedicine and Pharmacotherapy</i> , 2022, 147, 112677.	2.5	18
596	HDL maturation and remodelling. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2022, 1867, 159119.	1.2	3
599	Blood-based and Imaging Biomarkers of Atherosclerosis. <i>Cardiology in Review</i> , 2022, Publish Ahead of Print, .	0.6	1
600	Higher HDL Cholesterol Levels Decrease Susceptibility to COVID-19 Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1



#	ARTICLE	IF	CITATIONS
601	Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes. <i>Clinical Therapeutics</i> , 2022, 44, 331-348.	1.1	4
602	Cholesterol measurement and current guidelines. <i>Vnitřní Lékařství</i> , 2022, 68, 54-57.	0.1	2
603	Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation. <i>PLoS Biology</i> , 2022, 20, e3001547.	2.6	69
604	Plasma Proteome Profiling of Patients With In-stent Restenosis by Tandem Mass Tag-Based Quantitative Proteomics Approach. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 793405.	1.1	2
605	Understanding Myeloperoxidase-Induced Damage to HDL Structure and Function in the Vessel Wall: Implications for HDL-Based Therapies. <i>Antioxidants</i> , 2022, 11, 556.	2.2	8
606	HDL Receptor in <i>Schistosoma japonicum</i> Mediating Egg Embryonation: Potential Molecular Basis for High Prevalence of Cholesteryl Ester Transfer Protein Deficiency in East Asia. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 807289.	1.8	1
607	Intracoronary Application of Super-Saturated Oxygen to Reduce Infarct Size Following Myocardial Infarction. <i>Journal of Clinical Medicine</i> , 2022, 11, 1509.	1.0	6
608	The Role of High-Density Lipoprotein Cholesterol in 2022. <i>Current Atherosclerosis Reports</i> , 2022, 24, 365-377.	2.0	14
609	The Potential Clinical Benefit of Lowering Lipoprotein(a). <i>JAMA - Journal of the American Medical Association</i> , 2022, , .	3.8	6
610	Intravascular imaging assessment of pharmacotherapies targeting atherosclerosis: advantages and limitations in predicting their prognostic implications. <i>Cardiovascular Research</i> , 2023, 119, 121-135.	1.8	7
611	Complex association of apolipoprotein Eε-containing HDL with coronary artery disease burden in cardiovascular disease. <i>JCI Insight</i> , 2022, 7, .	2.3	10
612	Towards Personalized Therapy of Aortic Stenosis. <i>Journal of Personalized Medicine</i> , 2021, 11, 1292.	1.1	2
613	Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. <i>European Heart Journal</i> , 2022, 43, 1416-1424.	1.0	27
614	The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 622-632.	1.4	13
615	High-Density Lipoprotein Particle Subclasses in Statin-Treated Patients with Peripheral Artery Disease Predict Long-Term Survival. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1804-1813.	1.8	1
616	Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. <i>Revista Española De Cardiología</i> , 2022, 75, 429.e1-429.e104.	0.6	27
617	Phosphatidylserine enhances anti-inflammatory effects of reconstituted HDL in macrophages via distinct intracellular pathways. <i>FASEB Journal</i> , 2022, 36, e22274.	0.2	8
620	The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy. , 2022, 13, 491.		17

#	ARTICLE	IF	CITATIONS
621	Cholesterol transport in blood, lipoproteins, and cholesterol metabolism. , 2022, , 227-258.		0
622	Clinical strategies for reducing cholesterol levels. , 2022, , 853-901.		0
623	2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3235.	0.4	37
624	ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future. Current Atherosclerosis Reports, 2022, 24, 585-597.	2.0	8
625	Lymphocyte activation gene-3-associated protein networks are associated with HDL-cholesterol and mortality in the Trans-omics for Precision Medicine program. Communications Biology, 2022, 5, 362.	2.0	5
626	HDL and Cholesterol Ester Transfer Protein (CETP). Advances in Experimental Medicine and Biology, 2022, 1377, 13-26.	0.8	6
627	HDL and Diabetes. Advances in Experimental Medicine and Biology, 2022, 1377, 119-127.	0.8	4
628	Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations. JAMA Cardiology, 2022, 7, 672.	3.0	66
630	HDL as Bidirectional Lipid Vectors: Time for New Paradigms. Biomedicines, 2022, 10, 1180.	1.4	5
631	Existing and emerging strategies to lower Lipoprotein(a). Atherosclerosis, 2022, 349, 110-122.	0.4	36
632	Protein-based HDL subspecies: Rationale and association with cardiovascular disease, diabetes, stroke, and dementia. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159182.	1.2	5
633	Bariatric Surgery-induced High-density Lipoprotein Functionality Enhancement Is Associated With Reduced Inflammation. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2182-2194.	1.8	6
634	The potential of polygenic scores to improve cost and efficiency of clinical trials. Nature Communications, 2022, 13, .	5.8	19
635	Lowering low-density lipoprotein cholesterol: from mechanisms to therapies. , 2022, 1, 25-38.		10
636	Macular Degeneration and CETP Inhibition. JAMA Cardiology, 2022, 7, 774.	3.0	7
637	Macular Degeneration and CETP Inhibitionâ€”Reply. JAMA Cardiology, 0, , .	3.0	1
638	Causal associations of alcohol consumption with cardiovascular diseases and all-cause mortality among Chinese males. American Journal of Clinical Nutrition, 2022, 116, 771-779.	2.2	13
639	Effects of blood lipids and lipidâ€”modifying drugs on intracranial aneurysms. European Journal of Neurology, 2022, 29, 2967-2975.	1.7	6

#	ARTICLE	IF	CITATIONS
640	The mechanistic pathways of oxidative stress in aortic stenosis and clinical implications. <i>Theranostics</i> , 2022, 12, 5189-5203.	4.6	5
641	Editorial: Beyond Cardiovascular Disease: Challenging New Pathways in Lipid and Lipoprotein Metabolism. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	0
642	Extra- versus intracranial atherosclerosis: two facets of the same problem. <i>Russian Neurological Journal</i> , 2022, 27, 11-19.	0.1	1
643	Differential Effects of Genetically Determined Cholesterol Efflux Capacity on Coronary Artery Disease and Ischemic Stroke. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0
644	Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias. <i>Journal of Clinical Medicine</i> , 2022, 11, 3884.	1.0	22
645	HDL cholesterol levels and susceptibility to COVID-19. <i>EBioMedicine</i> , 2022, 82, 104166.	2.7	11
646	Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial. <i>European Heart Journal</i> , 2022, 43, 3947-3956.	1.0	14
647	Associations between the HDL-C/ApoA-I ratio and fasting glucose levels differ by glucose deciles, HDL-C/ApoA-I ratio ranges and sex. <i>Diabetes Research and Clinical Practice</i> , 2022, 190, 110021.	1.1	1
648	HIGH-DENSITY LIPOPROTEINS: FROM QUANTITATIVE MEASURES TO FUNCTIONAL ASSESSMENT AND THERAPY (REVIEW OF LITERATURE). <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2023, 67, .	0.2	0
649	Don't Turn Off the Tap! The Importance of Discovery Science to the Australian Cardiovascular Sector and Improving Clinical Outcomes Into the Future. <i>Heart Lung and Circulation</i> , 2022, , .	0.2	0
650	Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk. <i>Journal of Clinical Medicine</i> , 2022, 11, 4611.	1.0	5
651	Effect of CSL112 (apolipoprotein A-II [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross-study comparison. <i>Clinical and Translational Science</i> , 0, , .	1.5	3
652	Pharmacogenetics-guided CETP inhibition: an open question?. <i>European Heart Journal</i> , 2022, 43, 3957-3959.	1.0	3
653	Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. <i>Nature Medicine</i> , 2022, 28, 1672-1678.	15.2	56
654	Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9417.	1.8	17
655	Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	78
656	The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2023, 37, 101689.	2.2	3
657	Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease. <i>JAMA Cardiology</i> , 2022, 7, 955.	3.0	21

#	ARTICLE	IF	CITATIONS
658	Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2023, 9, 138-147.	1.4	14
659	Aortic valve stenosis: drivers of disease progression and drug targets for therapeutic opportunities. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 633-644.	1.5	2
660	Novel Role of CETP in Macrophages: Reduction of Mitochondrial Oxidants Production and Modulation of Cell Immune-Metabolic Profile. <i>Antioxidants</i> , 2022, 11, 1734.	2.2	10
661	Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?. <i>Lipids in Health and Disease</i> , 2022, 21, .	1.2	8
662	New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e4281-e4294.	1.8	5
663	Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segmentâ€“Elevation Myocardial Infarction: Results of REAL-TIMI 63B. <i>Circulation</i> , 2022, 146, 907-916.	1.6	10
664	Prevention is still the key to success. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 537-538.	1.4	0
665	Spotlight on very-low-density lipoprotein as a driver of cardiometabolic disorders: Implications for disease progression and mechanistic insights. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	6
666	Novel Therapeutic Strategies to Reduce Reperfusion Injury After Acute Myocardial Infarction. <i>Current Problems in Cardiology</i> , 2022, 47, 101398.	1.1	17
668	Risk assessment of remotely fatal cardiovascular events after elective percutaneous coronary intervention. <i>Complex Issues of Cardiovascular Diseases</i> , 2022, 11, 40-50.	0.3	0
670	Alterations of HDLâ€™s to piHDLâ€™s Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies. <i>Pharmaceuticals</i> , 2022, 15, 1278.	1.7	9
671	Inflammation in coronary artery disease-clinical implications of novel HDL-cholesterolâ€™related inflammatory parameters as predictors. <i>Coronary Artery Disease</i> , 2023, 34, 66-77.	0.3	11
672	Whole genome sequence analysis of blood lipid levels in >66,000 individuals. <i>Nature Communications</i> , 2022, 13, .	5.8	26
673	Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance. <i>Cardiology in Review</i> , 0, Publish Ahead of Print, .	0.6	1
674	Continuous and Marked Increase of Japanese HDL Associates Paradoxically with their Nutritional Shift. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, , .	0.9	1
675	Lipoprotein(a) and Cardiovascular Disease in Chinese Population. <i>JACC Asia</i> , 2022, 2, 653-665.	0.5	14
676	High-density lipoprotein revisited: biological functions and clinical relevance. <i>European Heart Journal</i> , 2023, 44, 1394-1407.	1.0	51
677	Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans. <i>Journal of Lipid Research</i> , 2023, 64, 100316.	2.0	0

#	ARTICLE	IF	CITATIONS
678	A review of therapeutic failures in late-stage clinical trials. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 389-399.	0.9	1
679	Antibiotic Resistance and Microbiota Response. <i>Current Pharmaceutical Design</i> , 2023, 29, 356-364.	0.9	10
680	Rationale and design of the Effects of intensive Systolic blood Pressure lowering treatment in reducing Risk of vascular events (ESPRIT): A multicenter open-label randomized controlled trial. <i>American Heart Journal</i> , 2023, 257, 93-102.	1.2	2
681	Anabolic androgenic steroids: How do they work and what are the risks?. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	27
682	Association of Plasma High-Density Lipoprotein Cholesterol Level With Risk of Fractures in Healthy Older Adults. <i>JAMA Cardiology</i> , 2023, 8, 268.	3.0	10
683	Very low HDL levels: clinical assessment and management. <i>Archives of Endocrinology and Metabolism</i> , 2023, 67, 3-18.	0.3	4
684	Study of effect modifiers of genetically predicted CETP reduction. <i>Genetic Epidemiology</i> , 0, .	0.6	0
685	Residual risks and evolving atherosclerotic plaques. <i>Molecular and Cellular Biochemistry</i> , 2023, 478, 2629-2643.	1.4	6
686	Type 2 Diabetes and HDL dysfunction: a key contributor to Glycemic Control. <i>Current Medicinal Chemistry</i> , 2023, 30, .	1.2	1
687	Using genetic association data to guide drug discovery and development: Review of methods and applications. <i>American Journal of Human Genetics</i> , 2023, 110, 195-214.	2.6	35
688	Individual and combined contributions of non-high-density lipoprotein cholesterol and brachial-ankle pulse wave velocity to cardiovascular disease risk: Results of a prospective study using the Kailuan cohort. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	0
689	Associations between serum high-density lipoprotein cholesterol levels and cause-specific mortality in a general population of 345,000 men and women aged 20-79 years. <i>International Journal of Epidemiology</i> , 2023, 52, 1257-1267.	0.9	4
690	Exploring the Active Compounds of Traditional Mongolian Medicine Baolier Capsule (BLEC) in Patients with Coronary Artery Disease (CAD) Based on Network Pharmacology Analysis, Molecular Docking and Experimental Validation. <i>Drug Design, Development and Therapy</i> , 0, Volume 17, 459-476.	2.0	0
691	Paraoxonase 1 and atherosclerosis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	8
692	Disease-modifying vs symptomatic treatments: Splitting over lumping. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 187-209.	1.0	5
693	HDL-Based Therapy: Vascular Protection at All Stages. <i>Biomedicines</i> , 2023, 11, 711.	1.4	1
694	Therapy of Elevated Lipoprotein(a). <i>Contemporary Cardiology</i> , 2023, , 347-357.	0.0	0
695	Structure-based mechanism and inhibition of cholesteryl ester transfer protein. <i>Current Atherosclerosis Reports</i> , 2023, 25, 155-166.	2.0	4

#	ARTICLE	IF	CITATIONS
696	Cholesteryl ester transfer protein inhibition is associated with reduced risk of Sjögren's syndrome. <i>Rheumatology</i> , 2023, 62, e258-e259.	0.9	0
697	Clinical Pharmacokinetics and Pharmacodynamics of CSL112. <i>Clinical Pharmacokinetics</i> , 2023, 62, 541-558.	1.6	3
698	Pathophysiology, emerging techniques for the assessment and novel treatment of aortic stenosis. <i>Open Heart</i> , 2023, 10, e002244.	0.9	1
699	Changes in high-density lipoprotein cholesterol with risk of Cardiovascular Disease among initially high-density lipoprotein-high participants. <i>Cardiovascular Diabetology</i> , 2023, 22, .	2.7	7
700	Serum amyloid A augments the atherogenic effects of cholesteryl ester transfer protein. <i>Journal of Lipid Research</i> , 2023, 64, 100365.	2.0	1
701	Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2023, 20, 600-616.	6.1	22
702	New Insights into Pathophysiology and New Risk Factors for ACS. <i>Journal of Clinical Medicine</i> , 2023, 12, 2883.	1.0	3
703	Are we seeing the light at the end of the tunnel for high lipoprotein(a)? <i>Lipoprotein(a)</i> , 2022, 1, .		0
704	Updated guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists. <i>Canadian Pharmacists Journal</i> , 2023, 156, 117-127.	0.4	2
706	Triglycerides, Triglyceride-Rich Lipoproteins, and High-Density Lipoprotein in Coronary Heart Disease Risk Assessment. , 2024, , 32-41.e2.		0
707	Treatment Guidelines Overview. , 2024, , 113-121.e2.		0
711	Diabetes and Atherogenic Dyslipidemia. , 2023, , 645-656.		0
715	Clinical Care of Lipids in People with Type 1 Diabetes. <i>Contemporary Diabetes</i> , 2023, , 755-778.	0.0	0
743	Cholesterol and lipids. , 2023, , .		0
755	HDL as a Treatment Target: Should We Abandon This Idea?. <i>Current Atherosclerosis Reports</i> , 0, , .	2.0	1
762	Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. <i>Current Atherosclerosis Reports</i> , 2024, 26, 35-44.	2.0	2
764	Atherosclerotic plaque stabilization and regression: a review of clinical evidence. <i>Nature Reviews Cardiology</i> , 0, , .	6.1	1